Identification of constitutive and steroid-dependent transactivation domains in the mouse oestrogen receptor

We have identified two transactivation domains in the mouse oestrogen receptor whose activities depend on the target promoter. The major domain is contained within the C-terminal portion of the protein and depends upon oestrogen binding for its activity. The location and oestrogen dependence of this domain has been confirmed using chimaeric receptors containing the Lex A DNA binding domain. Although transactivation by the C-terminal domain is dependent upon ligand binding the analysis of receptor deletion mutants has demonstrated that these two functions are not entirely coincident. The second transactivation domain lies within the N-terminal region and is active in the absence of oestradiol. The differences in oestrogen requirement for the activity of the two transactivation domains may account for the partial agonist activity of certain antihormones.     

斜胸叶蝉属一新种（同翅目：叶蝉总科：耳叶蝉科）

本文记述耳叶蝉科斜胸叶蝉属一新种:黄缘斜胸叶蝉Epiclinata flavomarinata sp.nov.。标本采自我国西藏。文中描述了新种的外部形态及雄性外生殖器构造特征,并与近似种进行比较,附有主要特征图。模式标本保存于中国科学院动物研究所。     

Dystrophin (Xp21), a New Phenotype Marker of Cultured Rat Aortic Myocytes

Dystropbin is a low-abundance cytoskeletal protein involved in the maintenance of membrane integrity in striated muscle. Very little is known about its role in smooth muscle. Utrophin (a dystropbin-related protein) is an ubiquitous protein whose role is still unclear. Changes in the expression of both proteins (if any) during phenotypic modulation of smooth muscle have not yet been reported. In contrast, modulated expression of heavy-molecular-weight caldesmon (h-CaD), a well-known specific regulatory protein of the contractile apparatus in smooth muscle, is well documented, along with its nonmuscle isoform, low-molecular-weight caldesmon (l-CaD), and other cytoskeletal proteins. We investigated three properties of cultured rat aortic smooth muscle cells: morphology, contractile ability, and expression of dystrophin, utrophin, h-CaD, and l-CaD. Cells were grown either in serum substitute supplemented medium (U-medium), where they reexpressed contractility, or in fetal calf serum-supplemented medium (F-medium), where they did not. It was found that only cultures grown in U-medium continued expressing dystrophin, even during the proliferation phase, contrary to cells grown in F-medium. However, when F-medium was changed for U-medium the cells recovered their contractility and reexpressed dystrophin. Expression of utrophin, h-CaD, and l-CaD was similar in both culture types. Dystrophin was demonstrated to be a true phenotype marker of cultured rat aortic smooth muscle cells, particularly with respect to their actual contractility.     

Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase.

Cyclins are pivotal in the coordinate regulation of the cell cycle. By physical association, they are able to activate at least one of the cyclin-dependent kinases, cdc2. How this association between the catalytic moiety and cyclins leads to subsequent activation of the kinase remains unclear. In this report, we describe experiments to investigate this event at a physical level. Our approach was to map the regions required on the cyclin A molecule for interaction with cdc2. We have mapped the contact regions to two small noncontiguous stretches of amino acids, residues 189 to 241 and 275 to 320, both located within the conserved cyclin box domain of the protein. We have further shown that this region not only represents a contact site for cdc2 but apparently represents an intact functional domain with respect to cdc2 activation. This region alone is sufficient to stimulate maturation when injected into immature Xenopus laevis oocytes. This observation implies that events leading to the activation of cdc2 kinase can be mediated through small regions of the cyclin molecule that are located in the cyclin box. These regions contain some of the most highly conserved residues found between all the cyclin members so far identified. This suggests that the cyclin family members may have conserved a similar mechanism to bind and activate cyclin-dependent kinases.     

Avian diversity and function across the world's most populous cities

Understanding the composition of urban wildlife communities is crucial to promote biodiversity, ecosystem function and links between nature and people. Using crowdsourced data from over five million eBird checklists, we examined the influence of urban characteristics on avian richness and function at 8443 sites within and across 137 global cities. Under half of the species from regional pools were recorded in cities, and we found a significant phylogenetic signal for urban tolerance. Site-level avian richness was positively influenced by the extent of open forest, cultivation and wetlands and avian functional diversity by wetlands. Functional diversity co-declined with richness, but groups including granivores and aquatic birds occurred even at species-poor sites. Cities in arid areas held a higher percentage of regional species richness. Our results indicate commonalities in the influence of habitat on richness and function, as well as lower niche availability, and phylogenetic diversity across the world's cities.     

益生菌辅助治疗牙周病的研究进展

牙周病是累及牙周支持组织的慢性感染性疾病。牙菌斑生物膜中的微生物及其代谢产物是其必不可少的始动因素,可导致口腔微生态失衡和宿主免疫反应,最终引起牙周病的发生发展。目前,牙周病的基础治疗主要是机械清除牙菌斑生物膜和牙石,但治疗效果具有局限性。益生菌通过产生抑菌物质、刺激局部免疫反应、与致病菌争夺黏膜受体和营养物质,从而改善口腔微生态平衡,促进牙周病的治疗。本文就近年来益生菌在牙周病治疗上的实验和临床研究、作用机制、安全性等进行综述,为将来益生菌辅助治疗牙周病的应用提供参考。     

新型免疫抑制剂brasilicardin A的研究进展

Brasilicardin A (BraA)是从致病性放线菌巴西诺卡菌(Nocardia brasiliensis) IFM 0406中发现的具有显著免疫抑制作用(IC50=0.057μg/mL)的二萜糖苷类化合物。BraA发挥免疫抑制活性的作用机制与现有临床常用的免疫抑制剂不同,BraA通过抑制氨基酸转运体L系统的转运进而影响T-淋巴细胞对氨基酸的摄入而发挥免疫抑制作用。相比目前已知的免疫抑制剂环孢菌素A、子囊霉素和他克莫司等,BraA在小鼠混合淋巴细胞反应中显示低毒、高效的优势。因此,BraA作为新型的免疫抑制剂,极具开发潜力,已成为全球免疫抑制剂发现新领域。但其结构复杂、合成困难,原菌种产率低且具有致病性,BraA及其类似物的获得已成为此类新型免疫抑制剂研究的瓶颈。本文综述了BraA的分子特征、药理活性、作用机制、目前获得的BraA类似物和衍生化方面的研究进展,以期为BraA及其类似物的高效生产提供参考。     

Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study.

OBJECTIVE: To determine whether raised plasma glucose concentration independently influences outcome after acute stroke or is a stress response reflecting increased stroke severity. DESIGN: Long-term follow up study of patients admitted to an acute stroke unit. SETTING: Western Infirmary, Glasgow. SUBJECTS: 811 patients with acute stroke confirmed by computed tomography. Analysis was restricted to the 750 non-diabetic patients. MAIN OUTCOME MEASURES: Survival time and placement three months after stroke. RESULTS: 645 patients (86%) had ischaemic stroke and 105 patients (14%) haemorrhagic stroke. Cox''s proportional hazards modelling with stratification according to Oxfordshire Community Stroke Project categories identified increased age (relative hazard 1.36 per decade; 95% confidence interval 1.21 to 1.53), haemorrhagic stroke (relative hazard 1.67; 1.22 to 2.28), time to resolution of symptoms > 72 hours (relative hazard 2.15; 1.15 to 4.05), and hyperglycaemia (relative hazard 1.87; 1.43 to 2.45) as predictors of mortality. The effect of glucose concentration on survival was greatest in the first month. CONCLUSIONS: Plasma glucose concentration above 8 mmol/l after acute stroke predicts a poor prognosis after correcting for age, stroke severity, and stroke subtype. Raised plasma glucose concentration is therefore unlikely to be solely a stress response and should arguably be treated actively. A randomised trial is warranted.